Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aydin Pooli

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
World Journal of Urology|May 13, 2018
Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapyIzak Faiena, Amirali Salmasi, Neil Mendhiratta, et al.
Urologic Oncology|September 20, 2018
Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinomaAmirali Salmasi, Izak Faiena, Andrew T Lenis, et al.
Urologic Oncology|November 18, 2018
Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?Aydin Pooli, Amirali Salmasi, Izak Faiena, et al.
Cancer Investigation|February 5, 2024
Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell CarcinomaCedric Lebacle, Aydin Pooli, Brian Shuch, et al.
Urologic Oncology|September 21, 2019
Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factorsAydin Pooli, Amirali Salmasi, David C Johnson, et al.
World Journal of Urology|September 30, 2018
Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelinesAlexander Upfill-Brown, Andrew T Lenis, Izak Faiena, et al.
European Urology Oncology|November 9, 2025
Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical TrialRaag Agrawal, Adam B Weiner, Julie Livingstone, et al.
European Urology Oncology|September 22, 2020
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center StudyAndrew T Lenis, Aydin Pooli, Patrick M Lec, et al.
Urologic Oncology|April 2, 2019
Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survivalAndrew T Lenis, Claire S Burton, Vishnukamal Golla, et al.
European Urology|September 25, 2020
Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) ClassifierPatrick D McGillivray, Daiki Ueno, Aydin Pooli, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
World Journal of Urology|May 13, 2018
Overall survival in patients with residual disease after radical cystectomy and neoadjuvant chemotherapyIzak Faiena, Amirali Salmasi, Neil Mendhiratta, et al.
Urologic Oncology|September 20, 2018
Association between renal mass biopsy and upstaging to perinephric fat involvement in a contemporary cohort of patients with clinical T1a renal cell carcinomaAmirali Salmasi, Izak Faiena, Andrew T Lenis, et al.
Urologic Oncology|November 18, 2018
Variation in surgical treatment patterns for patients with prostate cancer in the United States: Do patients in academic hospitals fare better?Aydin Pooli, Amirali Salmasi, Izak Faiena, et al.
Cancer Investigation|February 5, 2024
Gain of Chromosome 5q Predicts a Favorable Prognosis in Localized Renal Cell CarcinomaCedric Lebacle, Aydin Pooli, Brian Shuch, et al.
Urologic Oncology|September 21, 2019
Positive surgical margins at radical prostatectomy in the United States: Institutional variations and predictive factorsAydin Pooli, Amirali Salmasi, David C Johnson, et al.
World Journal of Urology|September 30, 2018
Treatment utilization and overall survival in patients receiving radical nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma: evaluation of updated treatment guidelinesAlexander Upfill-Brown, Andrew T Lenis, Izak Faiena, et al.
European Urology Oncology|November 9, 2025
Neoadjuvant Antiandrogen Therapy With or Without MEK or SRC Inhibition for Unfavorable-risk Prostate Cancer: A Phase 2 Randomized Clinical TrialRaag Agrawal, Adam B Weiner, Julie Livingstone, et al.
European Urology Oncology|September 22, 2020
Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging for Initial Staging of Treatment-naïve Intermediate- and High-risk Prostate Cancer: A Retrospective Single-center StudyAndrew T Lenis, Aydin Pooli, Patrick M Lec, et al.
Urologic Oncology|April 2, 2019
Cytoreductive nephrectomy in patients with metastatic renal cell carcinoma and venous thrombus-Trends and effect on overall survivalAndrew T Lenis, Claire S Burton, Vishnukamal Golla, et al.
European Urology|September 25, 2020
Distinguishing Benign Renal Tumors with an Oncocytic Gene Expression (ONEX) ClassifierPatrick D McGillivray, Daiki Ueno, Aydin Pooli, et al.
Pageof 3